Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

proximately 3.2 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology.
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... announced public offering of common stock have exercised their ... common stock at a price to the public of ... the offering is expected to be $64.8 million, after ...
(Date:3/2/2015)... , March 2, 2015 For the past 15 years, ... per year in the U.S. alone (U.S. Census Bureau 2012). Of ... minor fender benders BUT there are quite a few where the ... intrusion, which can obstruct the seatbelt release button or occupant injury. ... in any serious accidents in their lifetime but may still be ...
(Date:3/2/2015)... -- Leading patient advocacy organization Fight Colorectal Cancer and ... One Million Strong campaign to spotlight colorectal ... funds for colorectal cancer education, research and prevention while ... living in the United States ... every day. Showing Strength for Colorectal Cancer ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... , July 25, 2011 Pharmasset, Inc. (Nasdaq: ... to discovering, developing, and commercializing novel drugs to treat ... for the quarter ended June 30, 2011. ... quarter ended June 30, 2011 compared to $0.2 million ...
... VR Business Sales, Mergers & Acquisitions Charlotte, N.C. ... of Salisbury, NC.  This durable medical equipment provider specializes ... manual and power wheelchairs and scooters. "Penrod ... equipment providers I,ve seen.  The business generated a lot ...
Cached Medicine Technology:Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 2Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 3Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 4Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 5
(Date:3/2/2015)... 2015 New York singer/songwriter Richie ... delivering a plenary address entitled Finding the Music ... of Healing and Recovery at this year’s National ... Executive Summit (BHES).     , With more than 300 ... been recorded by some of the biggest names ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Atlantic Information ... of AIS’s Directory of Health Plans: 2015 , ... available on the U.S. health plan market, with enrollment ... the United States. , Available as a printed ... of enrollment trends in quick-view tables and charts, as ...
(Date:3/2/2015)... March 02, 2015 In light of ... anticoagulant Xarelto (rivaroxaban) tablets, Ford & Associates ... be helpful for future users, but may come too ... from taking the drug. The FDA has now included ... Adverse Reactions on Xarelto's label. The term “cytolytic hepatitis” ...
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... Children's Research Hospital have created a mouse model of a ... about //the gene therapy used to treat children that caused ... combined immunodeficiency (XSCID), is set into action by a mutation ... system from forming B and T lymphocytes. ...
... The manner of transmission of mosquito-borne viruses is well known; ... make an entry into the blood stream. But what happens ... of its victim. Researchers led by a Howard Hughes Medical ... point at a genetic element which helps the dengue virus ...
... study led by Volker Heussler of the Bernhard Nocht Institute ... malarial //parasite avoids the immune system by killing the liver ... that after infecting man, malarial parasites head to the liver ... was not known how the parasite avoids the immune system. ...
... gene which was identified by Professor Sir David Lane of ... gene using the mice model shows that the gene keeps ... Donehower of Baylor College of Medicine in Houston created some ... cancer. In another set he modified the gene and the ...
... Giving up your regular late-night snack may be hard, and ... change an area of the brain to expect the food// ... discovered. ,By training mice to eat at a ... turns on body-clock genes in a particular area of the ...
... isn't limited to soldiers or witnesses of a horrifying event. ... or heart surgery. Not only does PTSD cause emotional// and ... progression of heart disease, reports the August issue of the ... PTSD is that the trauma comes from within. Sufferers are ...
Cached Medicine News:Health News:Discovery In "Bubble Boy" Disease Gene Therapy 2Health News:Discovery In "Bubble Boy" Disease Gene Therapy 3Health News:Discovery In "Bubble Boy" Disease Gene Therapy 4Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3Health News:Timing of Food Consumption Activates Genes in Specific Brain Area 2
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... practitioners consider the HOPE nebulizer the gold standard ... made to put everything together in one convenient ... is our #11320 Adult HOPE Kit which contains ... and pediatric aerosol mask all in one set ...
... medication nebulizers offer a spill-proof design and ... a 45° angle. All medical nebulizers are ... variety of configurations are available., ,All ... ,Portex® medication nebulizers feature consistently fine ...
Medicine Products: